26
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, De Donato C, De Santis C, De Simone N, Felice VD, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy S, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. TRAPPED PROTON FLUXES AT LOW EARTH ORBITS MEASURED BY THE
PAMELA
EXPERIMENT. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/2041-8205/799/1/l4] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
27
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Danilchenko IA, De Donato C, De Santis C, De Simone N, Felice VD, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy S, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. MEASUREMENT OF BORON AND CARBON FLUXES IN COSMIC RAYS WITH THE PAMELA EXPERIMENT. ACTA ACUST UNITED AC 2014. [DOI: 10.1088/0004-637x/791/2/93] [Citation(s) in RCA: 115] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
28
|
Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014; 28:2336-43. [PMID: 24781017 PMCID: PMC4214904 DOI: 10.1038/leu.2014.142] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2014] [Accepted: 04/11/2014] [Indexed: 12/22/2022]
Abstract
With improved contemporary therapy, we re-assess long-term outcome in patients completing treatment for childhood acute lymphoblastic leukemia to determine when cure can be declared with a high degree of confidence. In 6 successive clinical trials between 1984 and 2007, 1291(84.5%) patients completed all therapy in continuous complete remission. The post-therapy cumulative risk of relapse or development of a second neoplasm and the event-free survival rate and overall survival were analyzed according to the presenting features and the three treatment periods defined by relative outcome. Over the three treatment periods, there has been progressive increase in the rate of event-free survival (65.2% vs. 74.8% vs. 85.1% [P<0.001]) and overall survival (76.5% vs. 81.1% vs. 91.7% [P<0.001]) at 10 years. The most important predictor of outcome after completion of therapy was the type of treatment. In the most recent treatment period, which omitted the use of prophylactic cranial irradiation, the post-treatment cumulative risk of relapse was 6.4%, death in remission 1.5%, and development of a second neoplasm 2.3% at 10 years, with all relapses except one occurring within 4 years off therapy. None of the 106 patients with the t(9;22)/BCR-ABL1, t(1;19)/TCF3-PBX1 or t(4;11)/MLL-AFF1 had relapsed after 2 years from completion of therapy. These findings demonstrate that with contemporary effective therapy that excludes cranial irradiation, approximately 6% of children with acute lymphoblastic leukemia may relapse after completion of treatment, and those who remain in remission at 4 years post-treatment may be considered cured (i.e., less than 1 % chance of relapse).
Collapse
|
29
|
Ricciarini SB, Adriani O, Barbarino G, Bazilevskaya G, Bellotti R, Boezio M, Bogomolov E, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, De Donato C, De Pascale M, De Santis C, De Simone N, Di Felice V, Formato V, Galper A, Karelin A, Kheymits M, Koldashov S, Koldobskiy S, Krutkov S, Kvashnin A, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov A, Menn W, Mergè M, Mikhailov V, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Sarkar R, Simon M, Scotti V, Sparvoli R, Spillantini P, Stozhkov Y, Vacchi A, Vannuccini E, Vasilyev G, Voronov S, Yurkin Y, Zampa G, Zampa N, Zverev V. PAMELA mission: heralding a new era in cosmic ray physics. EPJ WEB OF CONFERENCES 2014. [DOI: 10.1051/epjconf/20147100115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Bianco A, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, De Donato C, De Santis C, De Simone N, Di Felice V, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy SA, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stochaj SJ, Stockton JC, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. Cosmic-ray positron energy spectrum measured by PAMELA. PHYSICAL REVIEW LETTERS 2013; 111:081102. [PMID: 24010424 DOI: 10.1103/physrevlett.111.081102] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Indexed: 06/02/2023]
Abstract
Precision measurements of the positron component in the cosmic radiation provide important information about the propagation of cosmic rays and the nature of particle sources in our Galaxy. The satellite-borne experiment PAMELA has been used to make a new measurement of the cosmic-ray positron flux and fraction that extends previously published measurements up to 300 GeV in kinetic energy. The combined measurements of the cosmic-ray positron energy spectrum and fraction provide a unique tool to constrain interpretation models. During the recent solar minimum activity period from July 2006 to December 2009, approximately 24,500 positrons were observed. The results cannot be easily reconciled with purely secondary production, and additional sources of either astrophysical or exotic origin may be required.
Collapse
|
31
|
Sandlund JT, Pui CH, Zhou Y, Onciu M, Campana D, Hudson MM, Inaba H, Metzger ML, Bhojwani D, Ribeiro RC. Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002. Ann Oncol 2013; 24:2425-9. [PMID: 23788752 DOI: 10.1093/annonc/mdt221] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Reliable prognostic factors have not been established for advanced-stage pediatric lymphoblastic lymphoma (LL). We analyzed treatment outcomes and potential risk factors in children and adolescents with advanced-stage LL treated over a 40-year period. PATIENTS AND METHODS From 1962 through 2002, 146 patients (99 boys and 47 girls) with stage III (n = 111) or stage IV (n = 35) LL were treated at St Jude Children's Research Hospital. The five treatment eras were 1962-1975 (no protocol), 1975-1979 (NHL-75), 1979-1984 (Total 10 High), 1985-1992 (Pediatric Oncology Group protocol), and 1992-2002 (NHL13). Age at diagnosis was <10 years in 65 patients and ≥10 years in 81. RESULTS Outcomes improved markedly over successive treatment eras. NHL13 produced the highest 5-year event-free survival (EFS) estimate (82.9% ± 6.1% [SE]) compared with only 20.0% ± 8.0% during the earliest era. Treatment era (P < 0.0001) and age at diagnosis (<10 years versus ≥10 years, P = 0.0153) were independent prognostic factors, whereas disease stage, lactate dehydrogenase level, and presence of a pleural effusion were not. CONCLUSIONS Treatment era and age were the most important prognostic factors for children with advanced-stage LL. We suggest that a better assessment of early treatment response may help to identify patients with drug-resistant disease who require more intensive therapy.
Collapse
|
32
|
Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest 2012; 35:817-23. [PMID: 22080849 DOI: 10.3275/8102] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The few epidemiological data available in literature on neuroendocrine tumors (NET) are mainly based on Registry databases, missing therefore details on their clinical and natural history. AIM To investigate epidemiology, clinical presentation, and natural history of NET. DESIGN AND SETTING A large national retrospective survey was conducted in 13 Italian referral centers. Among 1203 NET, 820 originating in the thorax (T-NET), in the gastro-enteropancreatic tract (GEP-NET) or metastatic NET of unknown primary origin (U-NET) were enrolled in the study. RESULTS 93% had a sporadic and 7% a multiple endocrine neoplasia type 1 (MEN1)-associated tumor; 63% were GEP-NET, 33% T-NET, 4% U-NET. Pancreas and lung were the commonest primary sites. Poorly differentiated carcinomas were <10%, all sporadic. The incidence of NET had a linear increase from 1990 to 2007 in all the centers. The mean age at diagnosis was 60.0 ± 16.4 yr, significantly anticipated in MEN1 patients (47.7 ± 16.5 yr). Association with cigarette smoking and other non-NET cancer were more prevalent than in the general Italian population. The first symptoms of the disease were related to tumor burden in 46%, endocrine syndrome in 23%, while the diagnosis was fortuity in 29%. Insulin (37%) and serotonin (35%) were the most common hormonal hypersecretions. An advanced tumor stage was found in 42%, more frequently in the gut and thymus. No differences in the overall survival was observed between T-NET and GEP-NET and between sporadic and MEN1-associated tumors at 10 yr from diagnosis, while survival probability was dramatically reduced in U-NET. CONCLUSIONS The data obtained from this study furnish relevant information on epidemiology, natural history, and clinico-pathological features of NET, not available from the few published Register studies.
Collapse
|
33
|
Abstract
The aim of minimal residual disease (MRD) studies in patients with acute leukemia is to measure initial treatment response accurately, provide an assessment of the residual leukemic burden throughout therapy and detect relapse early. Therefore, information resulting from MRD monitoring can substantially improve many facets of clinical management. Methods for MRD detection, namely flow cytometry and PCR, have been applied to study the remission status of thousands of patients with acute lymphoblastic leukemia and acute myeloid leukemia. Collectively, the data indicate that MRD is a powerful prognostic indicator and an indispensable parameter for risk-adapted therapy. The current status of MRD in acute leukemia is briefly reviewed in this paper.
Collapse
|
34
|
Abstract
Natural killer (NK) cells can kill transformed cells and represent a promising tool for the treatment of cancer. Their function is governed by a balance of stimulatory and inhibitory signals triggered by surface receptors. Advances in NK cell therapy require the development of dependable methods for obtaining an adequate number of effector cells; additional activation or genetic modification may further increase their anticancer capacity. A method for NK cell expansion used in our laboratory relies on a genetically modified form of the K562 myeloid leukemia cell line, engineered to express a membrane-bound form of interleukin-15 and the ligand for the costimulatory molecule 4-1BB (CD137). Expanded NK cells can be transduced with genes encoding chimeric antigen receptors that stimulate tumor cell-specific cytotoxicity. These methods for NK cell expansion and genetic modification have been adapted to large-scale, clinical-grade, Current Good Manufacturing Practice conditions and support two active clinical trials. Summarized are current efforts for NK cell immunotherapy for cancer and future perspectives.
Collapse
|
35
|
Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, Onciu M, Cheng C, Coustan-Smith E, Bowman WP, Howard SC, Metzger ML, Inaba H, Leung W, Evans WE, Campana D, Relling MV, Pui CH. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012; 26:265-70. [PMID: 21869842 PMCID: PMC3345278 DOI: 10.1038/leu.2011.227] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Revised: 06/30/2011] [Accepted: 07/20/2011] [Indexed: 11/08/2022]
Abstract
ETV6-RUNX1 fusion is the most common genetic aberration in childhood acute lymphoblastic leukemia (ALL). To evaluate whether outcomes for this drug-sensitive leukemia are improved by contemporary risk-directed therapy, we studied clinical features, response and adverse events of 168 children with newly diagnosed ETV6-RUNX1-positive ALL on St Jude Total Therapy studies XIIIA (N=36), XIIIB (N=38) and XV (N=94). Results were compared with 494 ETV6-RUNX1-negative B-precursor ALL patients. ETV6-RUNX1 was associated with age 1-9 years, pre-treatment classification as low risk and lower levels of minimal residual disease (MRD) on day 19 of therapy (P<0.001). Event-free survival (EFS) or overall survival (OS) did not differ between patients with or without ETV6-RUNX1 in Total XIIIA or XIIIB. By contrast, in Total XV, patients with ETV6-RUNX1 had significantly better EFS (P=0.04; 5-year estimate, 96.8±2.4% versus 88.3±2.5%) and OS (P=0.04; 98.9±1.4% versus 93.7±1.8%) than those without ETV6-RUNX1. Within the ETV6-RUNX1 group, the only significant prognostic factor associated with higher OS was the treatment protocol Total XV (versus XIIIA or XIIIB) (P=0.01). Thus, the MRD-guided treatment schema including intensive asparaginase and high-dose methotrexate in the Total XV study produced significantly better outcomes than previous regimens and demonstrated that nearly all children with ETV6-RUNX1 ALL can be cured.
Collapse
|
36
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Borisov S, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Consiglio L, De Pascale MP, De Santis C, De Simone N, Di Felice V, Galper AM, Gillard W, Grishantseva L, Jerse G, Karelin AV, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Malvezzi V, Marcelli L, Mayorov AG, Menn W, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Nikonov N, Osteria G, Palma F, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Simon M, Sparvoli R, Spillantini P, Stochaj SJ, Stockton JC, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Wu J, Yurkin YT, Zampa G, Zampa N, Zverev VG. Cosmic-ray electron flux measured by the PAMELA experiment between 1 and 625 GeV. PHYSICAL REVIEW LETTERS 2011; 106:201101. [PMID: 21668214 DOI: 10.1103/physrevlett.106.201101] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Indexed: 05/30/2023]
Abstract
Precision measurements of the electron component in the cosmic radiation provide important information about the origin and propagation of cosmic rays in the Galaxy. Here we present new results regarding negatively charged electrons between 1 and 625 GeV performed by the satellite-borne experiment PAMELA. This is the first time that cosmic-ray e⁻ have been identified above 50 GeV. The electron spectrum can be described with a single power-law energy dependence with spectral index -3.18 ± 0.05 above the energy region influenced by the solar wind (> 30 GeV). No significant spectral features are observed and the data can be interpreted in terms of conventional diffusive propagation models. However, the data are also consistent with models including new cosmic-ray sources that could explain the rise in the positron fraction.
Collapse
|
37
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Borisov S, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Consiglio L, De Pascale MP, De Santis C, De Simone N, Di Felice V, Galper AM, Gillard W, Grishantseva L, Jerse G, Karelin AV, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Malvezzi V, Marcelli L, Mayorov AG, Menn W, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Nikonov N, Osteria G, Palma F, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Wu J, Zampa G, Zampa N, Zverev VG. PAMELA Measurements of Cosmic-Ray Proton and Helium Spectra. Science 2011; 332:69-72. [DOI: 10.1126/science.1199172] [Citation(s) in RCA: 593] [Impact Index Per Article: 45.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
38
|
Luszczek W, Morales-Tirado V, Woolard S, Van Der Merwe M, Shook D, Campana D, Pillai A. Expanded Human INKT Cells Exhibit Th2 Polarization and Direct Cytotoxicity Against Hematolymphoid Tumor Targets. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Borisov S, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Consiglio L, De Pascale MP, De Santis C, De Simone N, Di Felice V, Galper AM, Gillard W, Grishantseva L, Hofverberg P, Jerse G, Karelin AV, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malvezzi V, Marcelli L, Mayorov AG, Menn W, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Nikonov N, Osteria G, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Wu J, Yurkin YT, Zampa G, Zampa N, Zverev VG. PAMELA results on the cosmic-ray antiproton flux from 60 MeV to 180 GeV in kinetic energy. PHYSICAL REVIEW LETTERS 2010; 105:121101. [PMID: 20867623 DOI: 10.1103/physrevlett.105.121101] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2010] [Indexed: 05/29/2023]
Abstract
The satellite-borne experiment PAMELA has been used to make a new measurement of the cosmic-ray antiproton flux and the antiproton-to-proton flux ratio which extends previously published measurements down to 60 MeV and up to 180 GeV in kinetic energy. During 850 days of data acquisition approximately 1500 antiprotons were observed. The measurements are consistent with purely secondary production of antiprotons in the Galaxy. More precise secondary production models are required for a complete interpretation of the results.
Collapse
|
40
|
Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Bestani C, Merola E, Falconi M, Tomassetti P, delle Fave G. Risk and protective factors for midgut carcinoid tumors: Multicenter case-control study of prospectively evaluated patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, Cheng C, Howard SC, Metzger ML, Bhojwani D, Downing JR, Evans WE, Relling MV. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24:371-82. [PMID: 20010620 PMCID: PMC2820159 DOI: 10.1038/leu.2009.252] [Citation(s) in RCA: 224] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Accepted: 08/06/2009] [Indexed: 02/08/2023]
Abstract
We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significantly (P=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in the 1990s. Approximately 75% of patients treated in the 1980s and 80% in the 1990s were cured. Early intensive triple intrathecal therapy, together with more effective systemic therapy, including consolidation and reinduction treatment (Studies 13A and 13B) as well as dexamethasone (Study 13B), resulted in a very low rate of isolated central nervous system (CNS) relapse rate (<2%), despite the reduced use of cranial irradiation. Factors consistently associated with treatment outcome were age, leukocyte count, immunophenotype, DNA index, and minimal residual disease level after remission induction treatment. Owing to concerns about therapy-related secondary myeloid leukemia and brain tumors, in our current trials we reserve the use of etoposide for patients with refractory or relapsed leukemia undergoing hematopoietic stem cell transplantation, and cranial irradiation for those with CNS relapse. The next main challenge is to further increase cure rates while improving quality of life for all patients.
Collapse
|
42
|
Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, Dzekunov S, Peshwa M. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 2009; 17:147-54. [PMID: 19745843 DOI: 10.1038/cgt.2009.61] [Citation(s) in RCA: 107] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Natural killer (NK) cells hold promise for cancer therapy. NK cytotoxicity can be enhanced by expression of chimeric antigen receptors that re-direct specificity toward target cells by engaging cell surface molecules expressed on target cells. We developed a regulatory-compliant, scalable non-viral approach to engineer NK cells to be target-specific based on transfection of mRNA encoding chimeric receptors. Transfection of eGFP mRNA into ex vivo expanded NK cells (N=5) or purified unstimulated NK cells from peripheral blood (N=4) resulted in good cell viability with eGFP expression in 85+/-6% and 86+/-4%, 24 h after transfection, respectively. An mRNA encoding a receptor directed against CD19 (anti-CD19-BB-z) was also transfected into NK cells efficiently. Ex vivo expanded and purified unstimulated NK cells expressing anti-CD19-BB-z exhibited enhanced cytotoxicity against CD19(+) target cells resulting in > or =80% lysis of acute lymphoblastic leukemia and B-lineage chronic lymphocytic leukemia cells at effector target ratios lower than 10:1. The target-specific cytotoxicity for anti-CD19-BB-z mRNA-transfected NK cells was observed as early as 3 h after transfection and persisted for up to 3 days. The method described here should facilitate the clinical development of NK-based antigen-targeted immunotherapy for cancer.
Collapse
|
43
|
Pezzilli R, Morselli-Labate AM, Campana D, Casadei R, Brocchi E, Corinaldesi R. Evaluation of patient-reported outcome in subjects treated medically for acute pancreatitis: a follow-up study. Pancreatology 2009; 9:375-82. [PMID: 19451747 DOI: 10.1159/000181171] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2008] [Accepted: 10/29/2008] [Indexed: 12/11/2022]
Abstract
AIMS To explore the quality of life in patients treated medically during the acute phase of pancreatitis as well as at 2 and 12 months after discharge from the hospital. PATIENTS 40 patients were studied. The etiology of the pancreatitis was biliary causes in 31 patients and non-biliary causes in 9; mild disease was present in 29 patients and severe disease in 11. 30 patients completed the two surveys at 2 and 12 months after hospital discharge. METHODS The SF-12 and EORTC QLQ-C30 questionnaires were used for the purpose of the study. RESULTS The two physical and mental component summaries of SF-12, all the domains of EORTC QLQ-C30 (except for physical functioning and cognitive functioning) and some symptom scales of EORTC QLQ-C30 (fatigue, nausea/vomiting, pain, and constipation) were significantly impaired during the acute phase of pancreatitis. There was a significant improvement in the SF-12 physical component summary, and global health, role functioning, social functioning, nausea/vomiting, pain, dyspnea, and financial difficulties (EORTC QLQ-C30) at 2 months after discharge as compared to the basal evaluation. Similar results were found after 12 months except for the mental component score at 12-month evaluation, which was significantly impaired in acute pancreatitis patients in comparison to the norms. The physical functioning of the EORTC QLQ-C30 at basal evaluation was significantly impaired in patients with severe pancreatitis in comparison to patients with mild pancreatitis. CONCLUSIONS Two different patterns can be recognized in the quality of life of patients with acute pancreatitis: physical impairment is immediately present followed by mental impairment which appears progressively in the follow-up period.
Collapse
|
44
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Pascale MP, De Rosa G, De Simone N, Di Felice V, Galper AM, Grishantseva L, Hofverberg P, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malvezzi V, Marcelli L, Menn W, Mikhailov VV, Mocchiutti E, Orsi S, Osteria G, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. An anomalous positron abundance in cosmic rays with energies 1.5–100 GeV. Nature 2009; 458:607-9. [DOI: 10.1038/nature07942] [Citation(s) in RCA: 1589] [Impact Index Per Article: 105.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2008] [Accepted: 02/06/2009] [Indexed: 11/09/2022]
|
45
|
Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C, Sandlund JT, Ribeiro RC, Rubnitz JE, Howard SC, Downing JR, Evans WE, Relling MV, Pui CH. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009; 23:1406-9. [PMID: 19282835 DOI: 10.1038/leu.2009.42] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treated in four successive protocols at St Jude Children's Research Hospital. The 41 patients with the t(1;19) had a comparable event-free survival to that of the 694 patients with other B-cell precursor ALL (P=0.63; 84.2+/-7.1% (s.e.) vs 84.0+/-1.8% at 5 years). However, patients with the t(1;19) had a lower cumulative incidence of any hematological relapse (P=0.06; 0 vs 8.3+/-1.2% at 5 years) but a significantly higher incidence of central nervous system (CNS) relapse (P<0.001; 9.0+/-5.1% vs 1.0+/-0.4% at 5 years). In a multivariate analysis, the t(1;19) was an independent risk factor for isolated CNS relapse. These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse.
Collapse
|
46
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Pascale MP, De Rosa G, Fedele D, Galper AM, Grishantseva L, Hofverberg P, Leonov A, Koldashov SV, Krutkov SY, Kvashnin AN, Malvezzi V, Marcelli L, Menn W, Mikhailov VV, Minori M, Mocchiutti E, Nagni M, Orsi S, Osteria G, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Taddei E, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. New measurement of the antiproton-to-proton flux ratio up to 100 GeV in the cosmic radiation. PHYSICAL REVIEW LETTERS 2009; 102:051101. [PMID: 19257498 DOI: 10.1103/physrevlett.102.051101] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2008] [Revised: 11/21/2008] [Indexed: 05/27/2023]
Abstract
A new measurement of the cosmic-ray antiproton-to-proton flux ratio between 1 and 100 GeV is presented. The results were obtained with the PAMELA experiment, which was launched into low-Earth orbit on-board the Resurs-DK1 satellite on June 15th 2006. During 500 days of data collection a total of about 1000 antiprotons have been identified, including 100 above an energy of 20 GeV. The high-energy results are a tenfold improvement in statistics with respect to all previously published data. The data follow the trend expected from secondary production calculations and significantly constrain contributions from exotic sources, e.g., dark matter particle annihilations.
Collapse
|
47
|
Hochberg J, Mar B, Ayello J, Day N, van de Ven C, Ricci A, Gurnani L, Cairo E, Campana D, Cairo M. Significant Ex-Vivo Expansion of Cord Blood (CB) Natural Killer (NK) Cells and Concomitant Decrease in CB T-Cells by Genetically Reengineered K562 Cells (K562-mbIL15-41BBL). Biol Blood Marrow Transplant 2009. [DOI: 10.1016/j.bbmt.2008.12.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Lamba JK, Pounds S, Cao X, Downing JR, Campana D, Ribeiro RC, Pui CH, Rubnitz JE. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia 2008; 23:402-4. [PMID: 18615103 DOI: 10.1038/leu.2008.185] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
49
|
Campana D, Brocchi E, Tomassetti P. Multiple gastric endocrine tumours and gastrinomas of the duodenum in a patient with ZES MEN 1. Dig Liver Dis 2008; 40:476. [PMID: 18282753 DOI: 10.1016/j.dld.2007.11.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2007] [Revised: 11/23/2007] [Accepted: 11/29/2007] [Indexed: 12/11/2022]
|
50
|
Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15:337-42. [PMID: 18310299 DOI: 10.1677/erc-07-0251] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Gastric endocrine tumors associated with autoimmune chronic atrophic gastritis (gastric carcinoid type I) are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. For this reason, the role of octreotide in the treatment of these neoplastic lesions is controversial. Nine patients with more than five type I gastric endocrine tumors each <1 cm in size, without invasion of the muscularis propria and with Ki-67 index lower than 3%, were treated with long-acting somatostatin analogs for 12 months. After 6 months and again after 12 months, all the patients underwent upper gastrointestinal (GI) endoscopy with multiple biopsies. The plasma chromogranin A (CgA) levels and the gastrin levels in the serum were also determined. In all patients, the gastric neoplastic lesions disappeared after 12 months of somatostatin analog therapy. We also observed a significant reduction of CgA and gastrin levels at 6 and at 12 months of therapy as compared with the baseline values. We demonstrate that somatostatin analog treatment provokes the pathological regression of type I gastric carcinoids. This therapeutic approach should be considered as a valid option in selected patients with multiple type I gastric endocrine tumors.
Collapse
|